Cantor Fitzgerald: Reaffirms Merck & Co (MRK.US) rating_Stock Channel_Securities Star

Cantor Fitzgerald: Reaffirmed Merck & Co (MRK.US) rating from “overweight” to “overweight”, and adjusted the target price from $155.00 to $155.00.

Merck (MRK.US) Company Profile: Merck is a world-leading pharmaceutical company with innovative products for human and veterinary medicines. It provides health solutions through its prescription drugs, vaccines, biological therapies, animal health and consumer care products. It operates through the following divisions: Pharmaceuticals, Animal Health, Healthcare Services and Alliances. The pharmaceutical business includes human health pharmaceuticals and vaccine products. The Animal Health Division discovers, develops, manufactures and sells animal health products, such as pharmaceuticals and vaccine products, to prevent, treat and control diseases in livestock and companion animals, and sells them to veterinarians, distributors and animal producers. The services and solutions provided by the Healthcare Services Division focus on engagement, health analytics and clinical services to improve the value of care provided to patients. The Alliance segment includes the results of the company’s relationship with AstraZeneca LP in the sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

The above content is compiled by Securities Star based on public information and generated by intelligent algorithms and does not constitute investment advice.